Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype

Metastatic pheochromocytoma and paraganglioma (PPGL) have poor prognosis and limited therapeutic options. The recent advent of immunotherapies showing remarkable clinical efficacies against various cancer types offers the possibility of novel opportunities also for metastatic PPGL. Most PPGLs are pathogenically linked to inactivating mutations in genes encoding different succinate dehydrogenase (SDH) subunits. This causes activation of the hypoxia‐inducible factor 2 (HIF2)‐mediated transcriptional program in the absence of decreased intratumoral oxygen levels, a phenomenon known as pseudohypoxia. Genuine hypoxia in a tumor creates an immunosuppressive tumor microenvironment. However, the impact of pseudohypoxia in the immune landscape of tumors remains largely unexplored. In this study, tumoral expression of programmed death‐ligand 1 (PD‐L1) and HIF2α and tumor infiltration of CD8 T lymphocytes (CTLs) were examined in PPGL specimens from 102 patients. We assessed associations between PD‐L1, CTL infiltration, HIF2α expression, and the mutational status of SDH genes. Our results show that high PD‐L1 expression levels in tumor cells and CTL tumor infiltration were more frequent in metastatic than nonmetastatic PPGL. However, this phenotype was negatively associated with SDH mutations and high HIF2α protein expression. These data were validated by analysis of mRNA levels of genes expressing PD‐L1, CD8, and HIF2α in PPGL included in The Cancer Genome Atlas database. Further, PD‐L1 and CD8 expression was lower in norepinephrine than epinephrine‐secreting PPGL. This in silico analysis also revealed the low PD‐L1 or CD8 expression levels in tumors with inactivating mutations in VHL or activating mutations in the HIF2α‐coding gene, EPAS1, which, together with SDH‐mutated tumors, comprise the pseudohypoxic molecular subtype of PPGL. These findings suggest that pseudohypoxic tumor cells induce extrinsic signaling toward the immune cells promoting the development of an immunosuppressive environment. It also provides compelling support to explore the differential response of metastatic PPGL to immune checkpoint inhibitors. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

[1]  Yi Wang,et al.  Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy , 2022, Journal of Hematology & Oncology.

[2]  J. Enguita,et al.  Differential HIF2α Protein Expression in Human Carotid Body and Adrenal Medulla under Physiologic and Tumorigenic Conditions , 2022, Cancers.

[3]  C. Porta,et al.  Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. , 2022, Cancer treatment reviews.

[4]  Hongli Du,et al.  Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment , 2022, Frontiers in Immunology.

[5]  S. Fu,et al.  The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment , 2022, Frontiers in Immunology.

[6]  Yang Lu,et al.  Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work? , 2022, Cancers.

[7]  M. Simon,et al.  Hypoxia-Inducible Factors in Cancer , 2022, Cancer Research.

[8]  M. Tsuboi,et al.  Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. , 2022, Cancer cell.

[9]  M. Campbell,et al.  New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach , 2022, Current Oncology Reports.

[10]  W. Linehan,et al.  Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. , 2021, The New England journal of medicine.

[11]  Jill A. Madden,et al.  Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome. , 2021, The New England journal of medicine.

[12]  M. Koh,et al.  Revisiting the HIF switch in the tumor and its immune microenvironment. , 2021, Trends in cancer.

[13]  Greg M. Delgoffe,et al.  Hypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy. , 2021, Annual review of medicine.

[14]  Pei Zhang,et al.  Lactate in the tumour microenvironment: From immune modulation to therapy , 2021, EBioMedicine.

[15]  Ioanna K. Poutakidou,et al.  HIF2α regulates the synthesis and release of epinephrine in the adrenal medulla , 2021, Journal of molecular medicine.

[16]  G. Eisenhofer,et al.  Hypoxia-inducible Factor 2α: A Key Player in Tumorigenesis and Metastasis of Pheochromocytoma and Paraganglioma? , 2021, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[17]  G. Berchem,et al.  Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy , 2021, Oncogene.

[18]  Q. Cheng,et al.  Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer , 2021, Journal of experimental & clinical cancer research : CR.

[19]  R. Ferris,et al.  Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck , 2021, Journal for ImmunoTherapy of Cancer.

[20]  K. Olino,et al.  Metabolism of Innate Immune Cells in Cancer , 2021, Cancers.

[21]  J. Rothstein,et al.  Metabolic support of tumor-infiltrating regulatory T cells by lactic acid , 2020, Nature.

[22]  D. Wallace,et al.  Lactate Limits T Cell Proliferation via the NAD(H) Redox State , 2020, Cell reports.

[23]  M. Campbell,et al.  A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature , 2020, Frontiers in Endocrinology.

[24]  Alan Chuan-Ying Lai,et al.  HIF-2α is indispensable for regulatory T cell function , 2020, Nature Communications.

[25]  A. Naing,et al.  Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas , 2020, Cancers.

[26]  A. Lim,et al.  The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy , 2020, eLife.

[27]  E. Letouzé,et al.  TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition. , 2020, Cell reports.

[28]  Gustavo F. Bayón,et al.  Epigenetic deregulation of protocadherin PCDHGC3 in pheochromocytoma/paragangliomas associated with SDHB mutations. , 2019, The Journal of clinical endocrinology and metabolism.

[29]  Jian Sun,et al.  PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas. , 2019, Human pathology.

[30]  J. Galon,et al.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.

[31]  M. Balbín,et al.  Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas , 2018, Head & neck.

[32]  P. Dahia,et al.  EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease. , 2018, The New England journal of medicine.

[33]  M. Fraga,et al.  SDHC Promoter Methylation, a Novel Pathogenic Mechanism in Parasympathetic Paragangliomas , 2018, The Journal of clinical endocrinology and metabolism.

[34]  R. Dina,et al.  Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior , 2017, Oncoimmunology.

[35]  A. Lam Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours , 2017, Endocrine Pathology.

[36]  G. Semenza,et al.  Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. , 2016, Trends in cancer.

[37]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[38]  K. Tamada,et al.  Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy , 2015, Cancer science.

[39]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[40]  S. Srikantan,et al.  In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. , 2013, Endocrine-related cancer.

[41]  Electron Kebebew,et al.  Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. , 2012, The New England journal of medicine.

[42]  Lin Zhang,et al.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.

[43]  A. Chou,et al.  Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. , 2010, Human pathology.

[44]  W. Kaelin,et al.  Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. , 2008, Molecular cell.

[45]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[46]  Eyal Gottlieb,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[47]  P. Munson,et al.  Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. , 2004, Endocrine-related cancer.

[48]  C. Lewis,et al.  Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. , 2004, Blood.